Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma
Sarit Assouline(Jewish General Hospital), Peter Martin(Northwestern University), Solomon I. Hamburg(Tower Cancer Research Foundation), Ai‐Min Hui(Fosun Pharma (China)), Julie Chang(University of Wisconsin–Madison), Robert M. Rifkin(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Ruben Reyes(The University of Texas MD Anderson Cancer Center), Yu Jiang(AstraZeneca (Japan)), Bruce D. Cheson(Center for Cancer and Blood Disorders), Neeraj Gupta(Takeda (United States)), Yaping Shou(Takeda (United States)), Alessandra Di Bacco(Millennium Engineering and Integration (United States))
Cited by 8
Related Papers
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k